Add listing
    0
    Add listing

    Leman Biotech initiates clinical trial of CAR-T therapy for systemic lupus erythematosus Verified listing

    • Thursday, November 28, 2024 @ 12:00 am

    The First Affiliated Hospital of Zhejiang University School of Medicine successfully held the clinical launch meeting to include moderate to severe active systemic lupus erythematosus (SLE) into the investigator-initiated clinical trial (IIT) for the metabolically armed CD19 CAR-T cells (Meta10-19 Injection).

    Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the immune system attacking the body’s own tissues, leading to multi-organ damage. Based on disease activity and severity, SLE is classified into:

    • Mild SLE: Minimal symptoms with no major organ involvement.
    • Moderate SLE: Symptoms include organ damage such as arthritis, extensive rashes, vasculitis, or serous effusion.
    • Severe SLE: Life-threatening involvement of organs such as kidneys, brain, lungs, or blood, including conditions like rapidly progressive glomerulonephritis, neuropsychiatric lupus, lupus pneumonitis, and thrombotic thrombocytopenic purpura (TTP).

    While conventional treatments (e.g., NSAIDs, antimalarials, immunosuppressants, and corticosteroids) alleviate symptoms, they often lead to severe side effects and a high risk of relapse. Therefore, more effective, targeted therapies are urgently needed.

    Research has shown that abnormal B cell activation as central to SLE pathogenesis. B cells are involved in autoantibody production and immune dysregulation, making them a prime therapeutic target. Emerging evidence supports the use of CAR-T therapy, particularly CD19 CAR-T cells, as a breakthrough in SLE treatment, with clinical trials demonstrating promising efficacy and the potential to transform the disease trajectory.

    Go to patient recruitment information

    You may also be interested in